Durvalumab (0.1-5 mg/kg, intraperitoneal injection, twice a week, three weeks) suppresses human tumor growth in mouse models through T cell inhibition[1].
| Animal Model: | NOD/SCID mice with HPAC tumor, following coimplantation of primary human T cells; NOD/SCID mice with A375 tumor, following coimplantation of primary human T cells[2] |
| Dosage: | 5, 1, 0.1, and 0.01 mg/kg for NOD/SCID mice with HPAC tumor; 5, 1, and 0.1 mg/kg for NOD/SCID mice with A375 tumor |
| Administration: | Administration i.p.; twice per week; for 3 weeks |
| Result: | Significantly inhibited the tumor growth of both HPAC and A375 xenografts compared with an isotype-matched control antibody. |
